Cargando…

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-analysis included all seven randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sattar, Naveed, McGuire, Darren K., Pavo, Imre, Weerakkody, Govinda J., Nishiyama, Hiroshi, Wiese, Russell J., Zoungas, Sophia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938269/ https://www.ncbi.nlm.nih.gov/pubmed/35210595 http://dx.doi.org/10.1038/s41591-022-01707-4

Ejemplares similares

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C–Based Kidney Function: A SURPASS-4 Post Hoc Analysis
por: Heerspink, Hiddo J.L., et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes
por: McGuire, Darren K., et al.
Publicado: (2022)

THU296 Effect Of Tirzepatide In GADA-positive Individuals With T2D: A Post Hoc Analysis Of The SURPASS 2-5 Trials
por: Peters, Anne L, et al.
Publicado: (2023)

Action on patient safety can reduce health inequalities
por: Wade, Cian, et al.
Publicado: (2022)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme
por: Boye, Kristina S., et al.
Publicado: (2023)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
por: Dutta, Deep, et al.
Publicado: (2021)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
por: Sinha, Rachel, et al.
Publicado: (2023)

The epidemic of pre-diabetes: the medicine and the politics
por: Yudkin, John S, et al.
Publicado: (2014)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

Accuracy of circulating adiponectin for predicting gestational diabetes: a systematic review and meta-analysis
por: Iliodromiti, Stamatina, et al.
Publicado: (2016)

Roll-out of HIV pre-exposure prophylaxis: a gateway to mental health promotion
por: Ikeda, Daniel J, et al.
Publicado: (2021)

Pre-Messenger RNA Processing Factors in the Drosophila Genome
por: Mount, Stephen M., et al.
Publicado: (2000)

Role of asymptomatic and pre-symptomatic infections in covid-19 pandemic
por: Gao, Wenjing, et al.
Publicado: (2021)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Weight loss efficiency and safety of tirzepatide: A Systematic review
por: Lin, Fei, et al.
Publicado: (2023)

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022)

Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
por: Dutta, Palak, et al.
Publicado: (2023)

Spatial and temporal analysis of extreme sea level and storm surge events around the coastline of the UK
por: Haigh, Ivan D., et al.
Publicado: (2016)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

Health and social needs of migrant construction workers for big sporting events
por: Onarheim, Kristine Husøy, et al.
Publicado: (2021)

Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis
por: Tong, Keke, et al.
Publicado: (2023)

Improving the evidence on health inequities in migrant construction workers preparing for big sporting events
por: Flouris, Andreas D, et al.
Publicado: (2021)

Covid-19 as a long multiwave event: implications for responses to safeguard younger generations
por: Dhaliwal, Mandeep, et al.
Publicado: (2022)

Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
por: Karrar, Hani Raka, et al.
Publicado: (2023)

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
por: Heise, Tim, et al.
Publicado: (2023)

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
por: MacIsaac, Richard J., et al.
Publicado: (2023)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
por: Jung, Han Na, et al.
Publicado: (2022)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
por: Chiu, Nicholas, et al.
Publicado: (2022)

Mechanistic Study of Diketopiperazine Formation during Solid-Phase Peptide Synthesis of Tirzepatide
por: Wang, Jingyao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_922dvie1vrt4os4pt37scc60js